Anja Ehrhardt

Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

KIR3DS1 directs NK cell–mediated protection against human adenovirus infections

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors

Abstract B063: Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive T cell therapy of solid tumors

194. Adenoviruses Armed with TNFα and IL-2 Successfully Enable Adoptive T-Cell Therapy

410. Oncolytic Adenoviruses Armed with TNFa and IL-2 Induce Antitumor Immune Responses and Protection from Tumor Rechallenge

Enabling successful T-cell therapy of solid tumors with oncolytic adenoviruses armed with TNF&agr; and IL-2

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2

Oncolytic adenoviruses armed with TNFα and IL-2 enable successful adoptive T-cell therapy of solid tumors

Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds

RNAi suppressor P19 can be broadly exploited for enhanced adenovirus replication and microRNA knockdown experiments